NIH researchers have shown that sphingosine 1-phosphate receptor agonists such as Novartis' Gilenya could transiently reduce P glycoprotein-mediated drug efflux and enhance drug delivery to the brain. The group is evaluating the approach for improving drug delivery to brain tumors.